埃万妥单抗联合方案一线治疗适应症获批，肝转移亚组患者取得良好获益

埃万妥单抗联合方案中国获批，为肝转移患者带来显著生存获益

*以下内容仅供医疗卫生专业人士浏览。

审批编码：CP-555412

批准分发日期：2025/11/28

有效期：2026/11/28

参考文献：

[1]Zhou F, et al. The changing treatment landscape of EGFR-mutant non-small-cell lung cancer. Nat Rev Clin Oncol. 2025;22(2):95-116.

[2]Niu FY, Zhou Q, Yang JJ, et al. Distribution and prognosis of uncommon metastases from non-small cell lung cancer. BMC Cancer. 2016;16:149. Published 2016 Feb 24.

[3]Cho BC, et al. Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC. N Engl J Med. 2024;391(16):1486-1498.

[4]Ouint LE, et al. Distribution of distant metastases from newly diagnosed non - small cell lung cancer[J] .The Annals of Thoracic Surgery,1996,62(1):246-250

[5]Ren Y, et al. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget 2016;7:53245-53253

[6]Planchard D, et al; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23;389(21):1935-1948.

[7]Felip E, et al. Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA. Ann Oncol. 2024;35(9):805-816.

[8]Enriqueta Felip, et al. mivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR exon 20 insertion-mutated advanced NSCLC: Analysis of post-progression endpoints from PAPILLON. 2024 ELCC 2MO

[9]Spira AI, et al. Risk Factors Associated with Suboptimal Real-World Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Treated with Front-Line Recommended Therapy. Adv Ther. 2025;42(7):3547-3561.

[10]Yu HA, et al. Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.. JCO 41, 9074-9074(2023).

[11]Moores SL, et al. A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res. 2016;76(13):3942-3953.

*“医学界”力求所发表内容专业、可靠，但不对内容的准确性做出承诺；请相关各方在采用或以此作为决策依据时另行核查。